As we mark World Statistics Day, Carolyn McNamara, the Manager of the Research Data Management Team at The Institute of Cancer Research, London, explains how ...

A new drug is having a dramatic effect on shrinking lung cancer tumours, according to new research. A trial testing the drug zongertinib as a first treatment for people with advanced lung cancer who ...

Up to two in five advanced prostate cancer patients could be treated with a combination of two targeted drugs, according to new research. Findings by a team of scientists at The Institute of Cancer ...

Scientists have identified a more accurate way of predicting which patients with multiple myeloma, a type of blood cancer, are likely to relapse early following treatment. A study carried out by a ...

We are a world-leading cancer research institute, a charity, and a member institution of the University of London. Public donations and clinical partnerships are helping us to make the discoveries ...

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in ...

Kate Wilson was diagnosed with advanced ovarian cancer at the age of 43 and discovered she was carrying a BRCA gene mutation. She was prescribed a targeted drug called olaparib and five years on the ...

Cutting edge proton beam therapy is no better than intensity-modulated radiotherapy for treating people with head and neck cancer, according to new research. The nationwide TORPEdO trial funded by ...

The Institute of Cancer Research, London, has welcomed the approval of a new combination of two drugs for a rare form of ovarian cancer by the US regulatory body the Food and Drug Administration (FDA) ...

A spit test, where a sample can be collected at home, is more accurate at identifying future risk of prostate cancer for some men than the current standard PSA blood test, a new study reports. Results ...

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend that the targeted drug olaparib can be used for locally advanced or metastatic breast cancer. The ...

Two decades ago, a pivotal exchange between two scientists sparked a scientific and medical revolution. Professor Alan Ashworth, then Director of the Breast Cancer Now Toby Robins Research Centre at ...